Dss, Inc 10-Q for FY2022 Q2

Dss, Inc. (DSS)

10-Q 2022-09-14 For: 2022-06-30

Added on April 10, 2026

About this 10-Q

Dss, Inc filed this 10-Q on September 14, 2022, covering the quarter ended June 30, 2022 (FY2022 Q2).

Headline figures

Quarter ended June 30, 2022, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue: $11.77M; up 181.3% from $4.19M a year earlier
Net loss: $4.65M; compared with a net loss of $8.42M a year earlier
Diluted EPS: $0.05; compared with -$0.30 a year earlier

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

Large accelerated filer ☐	Accelerated filer ☐	Non-accelerated filer ☒	Smaller reporting company ☒
Emerging growth company ☐

Title of each class		Ticker symbol(s)		Name of each exchange on which registered
Common Stock, $0.02 par value per share		DSS		The NYSE American LLC

PART I	FINANCIAL INFORMATION	3
Item 1	Condensed Consolidated Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets as of June 30, 2022 and December 31, 2021	3
	Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2022 and 2021	4
	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2022 and 2021	5
	Condensed Consolidated Statement of Changes in Stockholders’ Equity for the six months ended June 30, 2022 and 2021	6
	Notes to Interim Condensed Consolidated Financial Statements	7
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	29
Item 4	Controls and Procedures	36

PART II	OTHER INFORMATION	37
Item 1	Legal Proceedings	37
Item 1A	Risk Factors	37
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	37
Item 3	Defaults upon Senior Securities	37
Item 4	Mine Safety Disclosures	37
Item 5	Other Information	37
Item 6	Exhibits	37

	June 30, 2022			December 31, 2021
ASSETS
Current assets:
Cash and cash equivalents	$	43,945,000		$	56,595,000
Accounts receivable, net		6,133,000			5,673,000
Inventory		9,132,000			8,261,000
Current portion of notes receivable		13,440,000			6,310,000
Prepaid expenses and other current assets		2,159,000			3,466,000
Total current assets		74,809,000			80,305,000

Property, plant and equipment, net		16,003,000			17,674,000
Investment in real estate, net		56,016,000			56,374,000
Other investments		15,386,000			11,001,000
Investment, equity method		982,000			1,080,000
Marketable securities		17,224,000			14,172,000
Notes receivable		539,000			5,878,000
Other assets		801,000			489,000
Right-of-use assets		10,700,000			498,000
Goodwill		56,606,000			56,606,000
Other intangible assets, net		33,882,000			38,630,000
Total assets	$	282,948,000		$	282,707,000

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable	$	2,112,000		$	1,920,000
Accrued expenses and deferred revenue		11,451,000			21,180,000
Other current liabilities		402,000			402,000
Current portion of lease liability		1,032,000			393,000
Current portion of long-term debt, net		46,711,000			3,916,000
Total current liabilities		61,708,000			27,811,000

Long-term debt, net		19,567,000			55,711,000
Long term lease liability		9,603,000			120,000
Other long-term liabilities		507,000			880,000

Commitments and contingencies (Note 9)

Stockholders’ equity
Preferred stock, $.02 par value; 47,000 shares authorized, zero shares issued and outstanding (zero on December 31, 2021); Liquidation value $1,000 per share, zero aggregate on December 31, 2021.		-			-
Common stock, $.02 par value; 200,000,000 shares authorized, 100,080,047 shares issued and outstanding (79,745,886 on December 31, 2021)		2,001,000			1,594,000
Additional paid-in capital		302,017,000			294,685,000
Accumulated deficit		(147,203,000	)		(134,503,000	)
Total stockholders’ equity		156,815,000			161,776,000
Non-controlling interest in subsidiaries		34,748,000			36,409,000
Total stockholders’ equity attributed to DSS stockholders		191,563,000			198,185,000

Total liabilities and stockholders’ equity	$	282,948,000		$	282,707,000

	2022			2021			2022			2021
	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2022			2021			2022			2021
Revenue:
Printed products	$	4,048,000		$	3,376,000		$	7,617,000		$	7,237,000
Rental income		1,508,000			-			3,171,000			-
Net investment income		145,000			-			274,000			-
Direct marketing		6,070,000			809,000			13,002,000			1,416,000
Total revenue		11,771,000			4,185,000			24,064,000			8,653,000

Costs and expenses:
Cost of revenue		7,670,000			3,231,000			16,285,000			6,638,000
Selling, general and administrative (including stock based compensation)		15,283,000			8,009,000			25,639,000			12,461,000
Total costs and expenses		22,953,000			11,240,000			41,924,000			19,099,000
Operating loss		(11,182,000	)		(7,055,000	)		(17,860,000	)		(10,446,000	)

Other income (expense):
Interest income		139,000			1,485,000			295,000			1,537,000
Other income (expense)		2,344,000			250,000			576,000			250,000
Interest expense		(121,000	)		(106,000	)		(1,499,000	)		(126,000	)
Gain on extinguishment of debt		110,000			-			110,000			116,000
Loss on equity method investment		(99,000	)		(332,000	)		(211,000	)		(911,000	)
Gain (loss) on investments		3,399,000			(6,821,000	)		3,823,000			(7,898,000	)
Gain on sale of assets		-			-			405,000			-
Loss from continuing operations before income taxes		(5,410,000	)		(12,579,000	)		(14,361,000	)		(17,478,000	)

Income tax benefit		-			1,854,000			-			2,691,000
Loss from continuing operations		(5,410,000	)		(10,725,000	)		(14,361,000	)		(14,787,000	)
Income from discontinued operations, net of tax		-			2,079,000			-			2,129,000
Net loss		(5,410,000	)		(8,646,000	)		(14,361,000	)		(12,658,000	)

Loss from continuing operations attributed to noncontrolling interest		758,000			228,000			1,661,000			259,000

Net loss attributable to common stockholders		(4,652,000	)		(8,418,000	)		(12,700,000	)		(12,399,000	)

Loss per common share:
Basic	$	(0.05	)	$	(0.30	)	$	(0.15	)	$	(0.53	)
Diluted	$	(0.05	)	$	(0.30	)	$	(0.15	)	$	(0.53	)

Earnings per common share - discontinued operations:
Basic	$	-		$	0.06		$	-		$	0.08
Diluted	$	-		$	0.06		$	-		$	0.08

Shares used in computing loss per common share:
Basic		90,822,875			34,888,054			85,641,957			27,203,137
Diluted		90,822,875			34,888,054			85,641,957			27,203,137

	2022			2021
Cash flows from operating activities:
Net loss from continuing operations	$	(14,361,000	)	$	(14,787,000	)
Adjustments to reconcile net loss from continuing operations to net cash used by operating activities:
Depreciation and amortization		6,425,000			1,335,000
Gain on allowance for obsolescence of inventory		(280,000	)		-
Stock based compensation		4,000			(15,000	)
Loss on equity method investment		211,000			911,000
Loss (gain) on investments		(3,823,000	)		7,898,000
Change in ROU assets and lease liabilities, net		(80,000	)		-
Gain on extinguishment of debt		(110,000	)		(116,000	)
Deferred tax benefit		-			(2,693,000	)
Accretion of debt discount, origination fee and prepaid interest		-			(1,698,000	)
Gain on sale of assets		(405,000	)		-
Impairment of notes receivable and other investments		1,745,000			-
Decrease (increase) in assets:
Accounts receivable		(460,000	)		366,000
Inventory		(591,000	)		(1,265,000	)
Prepaid expenses and other current assets		1,307,000			(559,000	)
Other assets		(312,000	)		112,000
Increase (decrease) in liabilities:
Accounts payable		192,000			159,000
Accrued expenses		(3,036,000	)		802,000
Other liabilities		(373,000	)		(698,000	)
Net cash used by operating activities		(13,947,000	)		(10,248,000	)

Cash flows from investing activities:
Purchase of property, plant and equipment		(976,000	)		(1,263,000	)
Purchase of real estate		(689,000	)		(6,565,000	)
Purchase of investment		-			(18,114,000	)
Purchase of marketable securities		(4,805,000	)		(8,789,000	)
Disposal of property, plant and equipment		2,557,000			-
Purchase of equity investment		-			(400,000	)
Sale of marketable securities		-			9,185,000
Issuance of new notes receivable		(3,362,000	)		(18,799,000	)
Payments received on notes receivable		863,000			-
Purchase of intangible assets		-			(585,000	)
Net cash used by investing activities		(6,412,000	)		(45,330,000	)

Cash flows from financing activities:
Payments of long-term debt		(169,000	)		(81,000	)
Borrowings of long-term debt		6,360,000			6,328,000
Deferred financing fees		-			(186,000	)
Issuances of common stock, net of issuance costs		1,518,000			106,772,000
Net cash provided by financing activities		7,709,000			112,833,000

Cash flows from discontinued operations:
Cash provided by discontinued operations		-			161,000
Cash provided by investing activities		-			3,046,000
Net cash used by discontinued operations		-			3,207,000

Net increase (decrease) in cash		(12,650,000	)		60,462,000
Cash and cash equivalents at beginning of period		56,595,000			5,183,000
Cash and cash equivalents at end of period	$	43,945,000		$	65,645,000

	Shares		Amount		Shares			Amount			Capital			Deficit			Equity			Subsidiary			Total
	Common Stock				Preferred Stock						Additional Paid-in			Accumulated			Total DSS			Non- controlling Interest in
	Shares		Amount		Shares			Amount			Capital			Deficit			Equity			Subsidiary			Total

Balance, December 31, 2021		79,746,000	$	1,594,000		-		$	-		$	294,685,000		$	(134,503,000	)	$	161,776,000		$	36,409,000		$	198,185,000
																		-
Issuance of common stock, net of expenses		3,987,000		80,000		-			-			1,438,000			-			1,518,000			-			1,518,000
Conversion of debt to equity in subsidiary		-		-		-			-			-			-			-						-
Stock based payments		16,347,000		327,000		-			-			5,894,000			-			6,221,000			-			6,221,000
Net loss		-		-		-			-			-			(12,700,000	)		(12,700,000	)		(1,661,000	)		(14,361,000	)
Balance, June 30, 2022		100,080,000	$	2,001,000		-		$	-		$	302,017,000		$	(147,203,000	)	$	156,815,000		$	34,748,000		$	191,563,000

Balance, December 31, 2020		5,836,000	$	116,000		43,000		$	1,000		$	174,380,000		$	(101,382,000	)	$	73,115,000			3,430,000		$	76,545,000
																		-						-
Issuance of common stock, net of expenses		55,184,000		1,104,000		-			-			105,712,000			-			106,816,000			-			106,816,000
Stock based payments		-		-		-			-			(15,000	)		-			(15,000	)		-			(15,000	)
Conversion of preferred stock		6,570,000		131,000		(43,000	)		(1,000	)		(130,000	)		-			-			-			-
Net loss		-		-		-			-			-			(12,399,000	)		(12,399,000	)		(259,000	)		(12,658,000	)
Balance, June 30, 2021		67,590,000	$	1,351,000		-		$	-		$	279,947,000		$	(113,781,000	)	$	167,517,000		$	3,171,000		$	170,688,000

	2022
	Adjusted Cost		Adjusted Cost		Unrealized Gain/(Loss)			Fair Value		Cash and Cash Equivalents		Restricted Cash		Marketable Securities		Notes Receivable		Investments
Cash	$	40,811,000	$	40,811,000	$	-		$	40,811,000	$	40,811,000	$	-	$	-	$	-	$	-
Level 1
Money Market Funds	$	3,134,000		3,134,000		-			3,134,000		3,134,000		-		-		-		-
Marketable Securities		18,977,000		18,999,000		(1,775,000	)		17,224,000		-		-		17,224,000		-		-
Level 2
Warrants				3,318,000		3,682,000			7,000,000		-		-		-		-		7,000,000
Convertible securities		-		1,023,000		1,135,000			2,158,000		-		-		-		-		2,158,000
Total	$	62,922,000	$	67,285,000	$	3,042,000		$	70,327,000	$	43,945,000	$	-	$	17,224,000	$	-	$	9,158,000


	Totals
2022		539,000
2023		1,162,000
2024		875,000
2025		849,000
2026		870,000
2027		891,000
After		5,997,000
Total lease payments		11,185,000
Less: Imputed Interest		(550,000	)
Present value of remaining lease payments	$	10,635,000

Current	$	1,032,000
Noncurrent	$	9,603,000

Weighted-average remaining lease term (years)		11.5

Weighted-average discount rate		4.2	%

	2022		2021

Cash paid for interest	$	5,395,000	$	126,000

Non-cash investing and financing activities:
Termination of right of use lease asset	$	-	$	(744,000	)
Termination of right of use lease liability	$	-	$	744,000
Shares received for loan origination fee	$	-	$	(3,000,000	)
Shares received for prepaid loan interest	$	-	$	(2,440,000	)
Right of use asset addition	$	9,895,000	$	-
Shares issued in lieu of bonus cash	$	6,216,000	$	-
Conversion of note receivable to equity	$	500,000	$	-


Three Months Ended June 30, 2022	Product Packaging		Commercial Lending		Direct Marketing			Biotechnology			Securities			Corporate			Total
Revenue	$	3,599,000	$	831,000	$	6,111,000		$	94,000		$	823,000		$	313,000		$	11,771,000
Depreciation and amortization		177,000		-		159,000			278,000			2,530,000			14,000			3,158,000
Interest expense		34,000		-		(321,000	)		-			408,000			-			121,000
Interest income		1,000		-		2,000			91,000			34,000			11,000			139,000
Amortized debt discount		-		-		-			-			-			-			-
Stock based compensation		-		-		-			-			-			-			-
Net income (loss) from continuing operations		365,000		25,000		892,000			(673,000	)		(3,332,000	)		(2,687,000	)		(5,410,000	)
Capital expenditures		254,000		-		12,000			-			2,000			1,000			269,000
Identifiable assets		26,688,000		52,416,000		52,267,000			56,524,000			85,436,000			9,617,000			282,948,000


Three Months Ended June 30,2021	Product Packaging		Commercial Lending		Direct Marketing			Biotechnology			Securities			Corporate			Total
Revenue	$	3,376,000	$	-	$	809,000		$	-		$	-		$	-		$	4,185,000
Depreciation and amortization		191,000		-		274,000			278,000			-			74,000			817,000
Interest expense		19,000		-		2,000			1,000			67,000			17,000			106,000
Stock based compensation		1,000		-		-			-			-			(31,000	)		(30,000	)
Impairment of goodwill		-		-		-									-			-
Net income (loss) from continuing operations		65,000		-		(5,985,000	)		(610,000	)		(173,000	)		(4,022,000	)		(10,725,000	)
Capital expenditures		1,202,000		-		-			-			6,565,000			(57,000	)		7,710,000
Identifiable assets		29,463,000		-		44,772,000			53,717,000			10,939,000			52,270,000			191,161,000


Six Months Ended June 30, 2022	Product Packaging		Commercial Lending		Direct Marketing			Biotechnology			Securities			Corporate			Total
Revenue	$	7,168,000	$	960,000	$	13,043,000		$	94,000		$	2,497,000		$	302,000		$	24,064,000
Depreciation and amortization		357,000		-		208,000			556,000			5,216,000			88,000			6,425,000
Interest expense		58,000		-		-			-			1,441,000			-			1,499,000
Stock based compensation		1,000		-		-			-			-			3,000			4,000
Income tax benefit		-		-		-			-			-			-			-
Net income (loss) from continuing operations		323,000		207,000		(3,472,000	)		(1,289,000	)		(5,838,000	)		(4,292,000	)		(14,361,000	)
Capital expenditures		943,000		-		14,000			-			15,000			4,000			976,000
Identifiable assets		26,688,000		52,416,000		52,267,000			56,524,000			85,436,000			9,617,000			282,948,000


Six Months Ended June 30,2021	Product Packaging		Commercial Lending		Direct Marketing			Biotechnology			Securities			Corporate			Total
Revenue	$	7,237,000	$	-	$	1,416,000		$	-		$	-		$	-		$	8,653,000
Depreciation and amortization		307,000		-		319,000			556,000			-			153,000			1,335,000
Interest expense		39,000		-		2,000			1,000			67,000			17,000			126,000
Stock based compensation		1,000		-		-			-			-			(16,000	)		(15,000	)
Income tax benefit		-		-		-			-			-			2,691,000			2,691,000
Net income (loss) from continuing operations		283,000		-		(7,785,000	)		(1,308,000	)		(231,000	)		(5,746,000	)		(14,787,000	)
Capital expenditures		1,202,000		-		6,000			-			6,565,000			55,000			7,828,000
Identifiable assets		29,463,000		-		44,772,000			53,717,000			10,939,000			52,270,000			191,161,000

Six months ended June 30, 2022
Packaging Printing and Fabrication	$	7,468,000
Commercial and Security Printing		149,000
Total Printed Products	$	7,617,000

Six months ended June 30, 2021
Packaging Printing and Fabrication	$	7,056,000
Commercial and Security Printing		181,000
Total Printed Products	$	7,237,000

Six months ended June 30, 2022
Direct Marketing Internet Sales	$	13,002,000
Total Direct Marketing	$	13,002,000

Six months ended June 30, 2021
Rental income	$	-
Total Rental Income	$	-

Three months ended March 31, 2022
Net investment income	$	274,000
Total Management fee income	$	274,000

Three months ended March 31, 2021
Management fee income	$	-
Total Management fee income	$	-

	●	REIT Management Fund: In March 2020, DSS Securities formed AMRE (“American Medical REIT”) and its management company AAMI (“AMRE Asset Management, Inc.) Through AAMI/AMRE, a medical real estate investment trust, fulfills community needs for quality healthcare facilities while enabling care providers to allocate their capital to growth and investment in their contemporary clinical and critical care businesses. Urban and suburban communities are in need of modern healthcare facilities that provide a range of medical outpatient services. The funds ultimate product is an investor opportunity in a managed medical real estate investment trust.

	●	Real Estate Title Services: Alset Title Company, Inc. provides buyers, sellers, and brokers alike confidence during big real estate transactions, not just in a transaction, but in the property itself. Through bundled services, Alset Title Company, Inc. provides it all from title searches and insurance to escrow agent assistance.

	●	Sentinel: Sentinel primarily operates as a financial intermediary, facilitating institutional trading of municipal and corporate bonds as well as preferred stock, and accelerates the trajectory of the DSS digital securities business.

	●	WestPark: WestPark, a company we hold a minority interest in, is a full-service investment banking and securities brokerage firm which serves the needs of both private and public companies worldwide, as well as individual and institutional investors.

	●	BMI: BMI is a private investment bank specializing in corporate finance advising, raising equity, and venture services, providing a global “one-stop” corporate consultancy to listed companies. From corporate finance to professional valuation, corporate communications to event management, BMI services companies in the US, Hong Kong, Singapore, Taiwan, Japan, Canada, and Australia.

	●	DSS AmericaFirst: DSS AmericaFirst is a suite of mutual funds managed by DSS Wealth Management. DSS AmericaFirst expects to expand into numerous investment platforms including additional mutual funds, exchange-traded funds, unit investment trusts, and closed-end funds. DSS AmericaFirst currently consists of four mutual funds that seek to outperform their respective benchmark indices by applying a quantitative rules-based approach to security selection.

	Three months ended June 30, 2022		Three months ended June 30, 2021		% Change			Six months ended June 30, 2022		Six months ended June 30, 2021		% Change

Printed products	$	4,048,000	$	3,376,000		20	%	$	7,617,000	$	7,237,000		5	%
Rental income		1,508,000		-		N/A			3,171,000		-		N/A
Net investment income		166,000		-		N/A			295,000		-		N/A
Direct marketing		6,070,000		809,000		650	%		13,002,000		1,416,000		818	%

Total Revenue	$	11,771,000	$	4,185,000		181	%	$	24,064,000	$	8,653,000		178	%

	Three months ended June 30, 2022		Three months ended June 30, 2021			% Change			Six months ended June 30, 2022		Six months ended June 30, 2021			% Change

Cost of revenue, inclusive of depreciation and amortization	$	7,670,000	$	3,231,000			137	%	$	16,285,000	$	6,638,000			145	%
Sales, general and administrative compensation		8,995,000		5,241,000			72	%		13,346,000		7,364,000			81	%
Professional fees		2,275,000		1,235,000			84	%		3,497,000		2,205,000			59	%
Stock based compensation		-		(30,000	)		-100	%		4,000		(15,000	)		-127	%
Sales and marketing		2,981,000		896,000			233	%		6,842,000		1,570,000			336	%
Rent and utilities		188,000		75,000			151	%		337,000		108,000			212	%
Research and development		206,000		211,000			-2	%		374,000		455,000			-18	%
Other operating expenses		638,000		381,000			67	%		1,239,000		774,000			60	%

Total costs and expenses	$	22,953,000	$	11,240,000			104	%	$	41,924,000	$	19,099,000			120	%

	Three months ended June 30, 2022			Three months ended June 30, 2021			% Change			Six months ended June 30, 2022			Six months ended June 30, 2021			% Change

Interest Income	$	139,000		$	1,485,000			-91	%	$	295,000		$	1,537,000			-81	%
Interest Expense		(121,000	)		(106,000	)		14	%		(1,499,000	)		(126,000	)		1090	%
Other Income (expense)		2,344,000			250,000			838	%		576,000			250,000			130	%
Gain (loss) on investments		3,399,000			(6,821,000	)		-150	%		3,823,000			(7,898,000	)		-148	%
Loss on equity method investment		(99,000	)		(332,000	)		-70	%		(211,000	)		(911,000	)		-77	%
Gain/(Loss) on extinguishment of debt		110,000			-			N/A			110,000			116,000			-5	%
Gain on disposal of operations, net of taxes		-			-			N/A			405,000			-			N/A

Total other income	$	5,772,000		$	(5,524,000	)		204	%	$	3,499,000		$	(7,032,000	)		150	%

Exhibit Number		Exhibit Description

3.1		Articles of Incorporation

3.2		Bylaws

10.1		Stock Purchase Agreement by and among DSS, Inc. and Alset EHome International, Inc. dated as of January 18, 2022 (incorporated by reference to Exhibit 10.1 to Form 8-K, filed with the Commission on January 19, 2022)

10.2		Stock Purchase Agreement by and among DSS, Inc. and Alset EHome International, Inc. dated as of January 18, 2022 (incorporated by reference to Exhibit 10.2 to Form 8-K, filed with the Commission on January 19, 2022)

10.3		Stock Purchase Agreement by and among DSS, Inc. and Alset EHome International, Inc. dated as of January 25, 2022 (incorporated by reference to Exhibit 10.1 to Form 8-K, filed with the Commission on January 25, 2022)

10.4		Assignment and Assumption Agreement by and between Alset International Limited and DSS, Inc. dated as of February 25, 2022 (incorporated by reference to Exhibit 10.1 to Form 8-K, filed with the Commission on February 25, 2022)

10.5		Convertible Promissory Note executed by American Medical REIT Inc. in favor of Alset International Limited in the principal amount of $8,350,000.00 dated October 29, 2021 (incorporated by reference to Exhibit 10.2 to Form 8-K, filed with the Commission on February 25, 2022)

10.6		Amendment to Stock Purchase Agreement made as of February 28, 2022 by and between DSS, Inc. and Alset EHome International, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K, filed with the Commission on March 1, 2022)

10.7		Stock Purchase Agreement by and among DSS, Inc. and Alset EHome International Inc. dated as of February 28, 2022 (incorporated by reference to Exhibit 10.2 to Form 8-K, filed with the Commission on March 1, 2022)

10.8		Agreement to Terminate Stock Purchase Agreement between DSS, Inc. and Alset EHome International Inc. (incorporated by reference to Exhibit 10.3 to Form 8-K, filed with the Commission on March 1, 2022)

10.9		Agreement to Terminate Stock Purchase Agreement between DSS, Inc. and Alset EHome International Inc. (incorporated by reference to Exhibit 10.4 to Form 8-K, filed with the Commission on March 1, 2022)

31.1		Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.*

31.2		Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer. *

32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.*

32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002.*

101.INS		Inline XBRL Instance Document*
101.SCH		Inline XBRL Taxonomy Extension Schema Document*
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document*
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document*
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)*

	DSS, INC.

September 14, 2022	By:	/s/ Frank D. Heuszel
		Frank D. Heuszel
		Chief Executive Officer
		(Principal Executive Officer)

September 14, 2022	By:	/s/ Todd D. Macko
		Todd D. Macko
		Chief Financial Officer

	(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.